B-CELL RECEPTOR CD22

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 19:48:59 GMT 2025` Edited by `admin` on `Tue Apr 01 19:48:59 GMT 2025`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	RCH7C9TW12
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

B-CELL RECEPTOR CD22

Common Name

English

CD-22

Preferred Name

English

CD22

Common Name

English

SIGLEC2

Common Name

English

SIGLEC-2

Common Name

English

SIALIC ACID-BINDING IG-LIKE LECTIN 2

Common Name

English

Code System Code Type Description

UNIPROT

P20273

Created by admin on Tue Apr 01 19:48:59 GMT 2025 , Edited by admin on Tue Apr 01 19:48:59 GMT 2025

PRIMARY

FDA UNII

RCH7C9TW12

Created by admin on Tue Apr 01 19:48:59 GMT 2025 , Edited by admin on Tue Apr 01 19:48:59 GMT 2025

PRIMARY

From	To
1_20	1_148
1_25	1_83
1_142	1_200
1_246	1_290
1_334	1_377
1_423	1_465
1_510	1_552
1_597	1_640

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_1
N	1_48
N	1_93
N	1_116
N	1_145
N	1_212
N	1_269
N	1_344
N	1_426
N	1_449
N	1_460
N	1_555
N	1_615

Related Record Type Details


					2F35K89X9W

YTTRIUM Y-90 EPRATUZUMAB

LIGAND->TARGET


					P93RUU11P7

INOTUZUMAB OZOGAMICIN

INHIBITOR -> TARGET

Interaction Type:

BINDING

Qualification:

Kd

Amount:


					4L3VFU7249

INDIUM IN-111 EPRATUZUMAB TETRAXETAN

RADIOLIGAND->TARGET

Amount:


					M8FA2JKW5P

Rezetamig

LIGAND->TARGET

Comments:

Pre-clinical

Amount:


					2F35K89X9W

YTTRIUM Y-90 EPRATUZUMAB

RADIOLIGAND->TARGET


					00NT1ETN9K

TRPH-222

CONJUGATED TOXIN->TARGET

Amount:


					2NDX4B6N8F

MOXETUMOMAB PASUDOTOX

INHIBITOR -> TARGET


					3062P60MH9

EPRATUZUMAB

INHIBITOR -> TARGET

Comments:

test

Amount:


					5GP3N2YX96

Lasmecabtagene Timgedleucel

CYTOTOXIC T-CELL->TARGET

Comments:

CD22+ B-cell acute lymphoblastic leukemia (B-ALL)

Interaction Type:

IN-VIVO

Amount:


					SVX9HP3ABN

SUCIRASLIMAB

LIGAND->TARGET

Amount:


					E6G32D6WP9

TECHNETIUM TC-99M EPRATUZUMAB

INHIBITOR -> TARGET

Amount:


					J36232195E

YTTRIUM Y-90 EPRATUZUMAB TETRAXETAN

INHIBITOR -> TARGET


					4WQE3D6M5H

Mozistobart Zoratolimod

LIGAND->TARGET

Interaction Type:

PRECLINICAL

Amount:


					2NDX4B6N8F

MOXETUMOMAB PASUDOTOX

CONJUGATED TOXIN->TARGET


					UC47AV3PU8

INOTUZUMAB

LIGAND->TARGET

Interaction Type:

BINDING

Qualification:

Kd

Amount:


					4BEJ6K4DQ9

Firicabtagene Autoleucel

INHIBITOR -> TARGET

Amount:


					V3JBG9247U

Tinocabtagene Autoleucel

LIGAND->TARGET

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID SUBSTITUTION	[1_706] [1_707] [1_720]		S		DEXFOSFOSERINE	VI4F0K069V

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL